Renovia Announces FDA 510(k) Clearance of Next-Generation leva® Pelvic Digital Therapeutic

Boston, MA – November 25, 2019 – Renovia Inc. (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic device and app technologies for women with pelvic floor disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the next-generation leva® Pelvic Digital Therapeutic for the strengthening of pelvic floor muscles and the treatment of stress, mixed and mild to moderate urgency urinary incontinence (UI) in women.